February 2, 2006—The FDA is fast-tracking an oral protease inhibitor to treat hepatitis C because it’s doing well in patients who don’t respond to the two treatments now available: pegylated interferon and ribavirin. The drug, called SCH 503034, shows promise both as monotherapy and along with pegylated interferon. Fast-track status should speed up its arrival on drug store shelves.